Skip to Main Content

Advertisement

Skip Nav Destination

Ixazomib Benefit Persists Despite Prior Therapy in TOURMALINE-MM1 Subset Analysis

December 30, 2021
María-Victoria Mateos, MD, PhD, shares the results of a subset analysis of TOURMALINE-MM1, which showed that patients with prior exposure to proteasome inhibitors still benefited from ixazomib treatment.

Advertisement

Connect with us:

CURRENT ISSUE
September 2022

Advertisement

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement